<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866395</url>
  </required_header>
  <id_info>
    <org_study_id>04091990</org_study_id>
    <nct_id>NCT03866395</nct_id>
  </id_info>
  <brief_title>Effects of Ivabradine on Residual Myocardial Ischemia After PCI</brief_title>
  <official_title>Effects of Ivabradine on Residual Myocardial Ischemia After PCI Evaluated by Stress Echocardiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Policlinico Umberto I</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Policlinico Umberto I</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized pharmacological study evaluating the effects of ivabradine in patients
      with residual angina after PCI. The role of ivabradine in patients with angina, without
      systolic dysfunction, is not yet clear. The investigators performed in all patients an
      echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of
      exercise tolerance and diastolic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND. Residual angina after PCI is a frequently-occurring disease. Ivabradine improves
      symptoms but its role in patients without left-ventricular systolic dysfunction is still
      unclear. The aim was to quantify the effects of ivabradine in terms of MVO2 indicators and
      diastolic function.

      METHODS. 28 consecutive patients with residual angina after PCI were randomized to ivabradine
      5 mg twice/day(IG) or standard therapy(CG). All patients performed a stress echocardiography
      at the enrollment and after 30 days. Myocardial oxygen consumption was estimated from: double
      product(DP); triple product(TP) integrating DP with ejection-time(ET). Diastolic function was
      evaluated determining E and A waves, E' measurements and E/E' ratio both at rest and at the
      peak of exercise.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2015</start_date>
  <completion_date type="Actual">March 7, 2017</completion_date>
  <primary_completion_date type="Actual">March 7, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Double product (DP) calculated as a product between HR and systolic blood pressure. (unit of measure: beats per minute x mmHg)</measure>
    <time_frame>30 days</time_frame>
    <description>These, indirectly, reflect the true myocardial oxygen consumption (MVO2) and the improvement of mechanical load that the ventricle can withstand at different levels of exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triple product (TP), calculated as a product between HR, systolic blood pressure and ejection time. (unit of measure: beats per minute x mmHg x msec)</measure>
    <time_frame>30 days</time_frame>
    <description>These, indirectly, reflect the true myocardial oxygen consumption (MVO2) and the improvement of mechanical load that the ventricle can withstand at different levels of exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chronotropic reserve (unit of measure: beats per minute)</measure>
    <time_frame>30 days</time_frame>
    <description>difference between resting heart rate and maximum heart rate at peak exercise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscular work (unit of measure: watt)</measure>
    <time_frame>30 days</time_frame>
    <description>These, indirectly, reflect the myocardial oxygen consumption (MVO2) and the improvement of mechanical load that the ventricle can withstand at different levels of exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>diastolic function: PW Doppler E wave (unit of measure: cm/sec)</measure>
    <time_frame>30 days</time_frame>
    <description>ventricular filling echocardiographic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic function: TDI derived E' measurements (unit of measure: cm/sec)</measure>
    <time_frame>30 days</time_frame>
    <description>ventricular filling echocardiographic parameter. Mitral annular E' velocity was estimated as the average between lateral and septal velocity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic function: PW Doppler A wave (unit of measure: cm/sec)</measure>
    <time_frame>30 days</time_frame>
    <description>ventricular filling echocardiographic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E/E' ratio</measure>
    <time_frame>30 days</time_frame>
    <description>ventricular filling echocardiographic parameter. TDI derived E' measurements (unit of measure: cm/sec). PW Doppler E wave (unit of measure: cm/sec)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Angina Pectoris, Stable</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>drug therapy according to the guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivabradine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug therapy according to the guidelines + Ivabradine 5 mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine 5 mg twice a day</description>
    <arm_group_label>Ivabradine Group</arm_group_label>
    <other_name>Procoralan</other_name>
    <other_name>Corlentor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary artery disease with chronic stable angina for more than three months
             (Canadian Cardiovascular Society-CCS-class I-III);

          -  percutaneous revascularization with stent implantation at least one;

          -  signs/symptoms of residual ischemia; sinus rhythm; HR ≥ 70 bpm at rest;

          -  ability to perform an echocardiogram stress test with the tilting bicycle stress test
             (BST);

          -  good acoustic window;

          -  age ≥ 18 years.

        Exclusion Criteria:

          -  drugs intolerance or hypersensitivity

          -  EF ≤ 40 %

          -  NYHA class III to IV;

          -  CCS IV

          -  atrial fibrillation or flutter

          -  presence of a pacemaker or implantable defibrillator

          -  II or III degree AV block

          -  HR ≤ 70 bpm at rest or sick sinus syndrome

          -  any condition that could interfere with the ability to exercise stress test like
             Wolff- Parkinson-White syndrome, left bundle branch block, left ventricular
             hypertrophy;

          -  rate-corrected QT interval (QTc) greater than 500 ms or the use of drugs that prolong
             the QTc interval

          -  symptomatic hypotension or uncontrolled hypertension (systolic blood pressure at rest
             ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg)

          -  severe liver disease and severe renal impairment (creatinine clearance ≤ 30 ml/min)

          -  electrolyte disorders

          -  uncontrolled thyroid disease

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Mancone</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular disease, Sapienza, University of Rome, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massimo Mancone</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Policlinico Umberto I</investigator_affiliation>
    <investigator_full_name>Massimo Mancone</investigator_full_name>
    <investigator_title>(MD, PhD) Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stable angina</keyword>
  <keyword>coronary artery diseases</keyword>
  <keyword>heart rate</keyword>
  <keyword>exercise tolerability</keyword>
  <keyword>diastolic function</keyword>
  <keyword>ivabradine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03866395/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

